VEGFA and neoplasm: Considering the SIRT local tumor control and the modulation on inflammation and neoangiogenesis of anti-VEGF therapies that may overcome radiation resistance, several studies evaluated the combination of SIRT and TKIs in patients with advanced HCC [33–36].